Αρχική World News FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small... World News FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma Από Ogkologos - 4 Φεβρουαρίου, 2026 579 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BRUIN-CLL-321 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ASCO20 Virtual Research Round Up Podcast: Central Nervous System Tumors and... 3 Σεπτεμβρίου, 2020 Mom Wants Disney To Ban Childless Adults From Their Theme Parks 29 Ιουλίου, 2019 Significant iDFS Benefit with Adding Ribociclib to a Nonsteroidal Aromatase Inhibitor... 26 Μαρτίου, 2024 ESMO Calls for Cancer to Be at the Core of the... 10 Ιουνίου, 2025 Φόρτωση περισσοτέρων HOT NEWS HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy... Sodium Thiosulfate Prevents Cisplatin-Induced Hearing Loss in Some Children Celebrating 10 years of partnership with NIVEA Sun ESMO Sarcoma and Rare Cancers Congress 2024